Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Hanmi Pharm. Co., Ltd.
  6. Summary
    A128940   KR7128940004

HANMI PHARM. CO., LTD.

(A128940)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
303500 302500 303000 299500 301000 Last
18779 18496 13721 19367 20470 Volume
+1.17% -0.33% +0.17% -1.16% +0.50% Change
Estimated financial data (e)
Sales 2021 1 122 B 0,95 B 0,95 B
Net income 2021 49,7 B 0,04 B 0,04 B
Net Debt 2021 586 B 0,50 B 0,50 B
P/E ratio 2021 73,0x
Yield 2021 0,16%
Sales 2022 1 203 B 1,02 B 1,02 B
Net income 2022 66,8 B 0,06 B 0,06 B
Net Debt 2022 477 B 0,40 B 0,40 B
P/E ratio 2022 54,4x
Yield 2022 0,16%
Capitalization 3 607 B 3 058 M 3 052 M
EV / Sales 2021 3,74x
EV / Sales 2022 3,40x
Nbr of Employees 2 155
Free-Float 50,0%
More Financials
Company
Hanmi Pharm Co Ltd is a Korea-based company principally engaged in the manufacturing and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Ratings of Hanmi Pharm. Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about HANMI PHARM. CO., LTD.
07/26MARKET CHATTER : South Korea's Hanmi Pharm, Legochem Biosciences to Develop Canc..
MT
07/05S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
07/04S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
06/29Hanmi Pharmaceutical Finds New Innovative Potential for Efpeglenatide
CI
05/17South Korea's Genexine signs COVID-19 vaccine candidate manufacturing deal wi..
RE
04/08MARKET CHATTER : US FDA Grants Fast Track Designation to Hanmi's Short-Bowel Syn..
MT
01/21MARKET CHATTER : FDA Approves Phase 2 Clinical Trials of Hanmi's Orphan Drugs
MT
01/19MARKET CHATTER : Hanmi Pharmaceutical Offers to Manufacture COVID-19 Vaccines
MT
01/18HANMI SCIENCE : Pharmaceutical expects U.S. FDA approval for 2 new drugs
AQ
01/12HANMI SCIENCE : presents solution package strategy to potentially overcome COVID..
AQ
01/06MARKET CHATTER : Shares of Korean Drug Makers Rise on Rumored Moderna Vaccine De..
MT
2020MARKET CHATTER : Top South Korean Pharma Companies' Third Quarter Results Surpas..
MT
2020Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efin..
CI
2020HANMI PHARM : FDA Grants Fast Track Designation for Hanmi LAPSTriple Agonist
AQ
2020Hanmi Pharmaceutical Reports Revenue Results for the Year 2019
CI
More news
News in other languages on HANMI PHARM. CO., LTD.
2015Le plan stratégique de Sanofi ne convainc pas le marché
2015SANOFI : signe un accord de licence avec Hanmi pour le développement d'antidiabé..
More news
Chart HANMI PHARM. CO., LTD.
Duration : Period :
Hanmi Pharm. Co., Ltd. Technical Analysis Chart | A128940 | KR7128940004 | MarketScreener
Technical analysis trends HANMI PHARM. CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 301 000,00 KRW
Average target price 371 846,15 KRW
Spread / Average Target 23,5%
EPS Revisions
Managers and Directors
Jong-Su Woo Co-President, Co-CEO & Director
Se-Chang Kwon Co-President, Co-CEO & Director
Jong-Yoon Lim Co-President, Director & Head-Business Development
Gwi-Hyun Seo Senior Managing Director & Head-Research Center
In-Guk Hwang Compliance Officer & Head-Audit Team